https://kumel.medlib.dsmc.or.kr/handle/2015.oak/29788 2026-03-21T12:08:25Z https://kumel.medlib.dsmc.or.kr/handle/2015.oak/46495 Title: Adenosine A(2A) receptor agonist polydeoxyribonucleotide ameliorates acetic acid-induced ulcerative colitis via modulating PI3K/Akt/VEGF signaling pathway Author(s): Junglok Lee; Il-Gyu Ko; Moonhyung Lee; Lakkyong Hwang; Sang-Hoon Kim; Hyeon Jeon; Hyeong Chan Shin; SeungHwan Lee; Su Bee Park; Hyoung Il Choi; Kwang Ro Joo; Jae Myung Cha; Hyun Phil Shin; Jung Won Jeon Abstract: Ulcerative colitis (UC) is a chronic inflammatory bowel disease caused by an abnormal immune response. Polydeoxyribonucleotide (PDRN), which acts on adenosine A2A receptors (A2AR), inhibits the secretion of pro-inflammatory cytokines and exhibits anti-inflammatory effects. We aimed to elucidate the effects of PDRN on acetic acid-induced UC rats. After anesthetizing the rats, acetic acid was diluted to 5 % in 0.9 % saline and administered directly into the colon at 1.0 mL per animal. Three days after acetic acid injection, the rats in the drug treatment group were intraperitoneally injected with 0.5 mL saline containing 8 mg/kg PDRN once daily for 10 days. To determine whether the effect of PDRN was mediated by A2AR, 8 mg/kg 7-dimethyl-1-propargylxanthine (DMPX), an A2AR antagonist, was administered together with PDRN. UC induction caused colonic damage, with increases in stool score, colonic wet weight, and ulcer score. UC induction increased the expression of pro-inflammatory cytokines and activated the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, while the expression of cyclic adenosine-3′,5′-monophosphate (cAMP) and vascular endothelial growth factor (VEGF) was decreased. PDRN treatment alleviated histological damage and colonic conditions. PDRN treatment suppressed the expression of pro-inflammatory cytokines and factors related to the PI3K/Akt pathway, while increasing the expression of cAMP and VEGF. Combined treatment with PDRN and DMPX completely abolished the effect of PDRN on UC, indicating that the action of PDRN occurs through A2AR. The present results showed that PDRN could be considered as a novel therapeutic agent for treating UC. 2024-12-31T15:00:00Z https://kumel.medlib.dsmc.or.kr/handle/2015.oak/46488 Title: Prognostic Significance of RBM3 Expression in Epithelial Ovarian Cancer: A Tissue Microarray-Based Study Author(s): Hyeong Chan Shin; Hye Won Lee; So-Jin Shin; Sun Young Kwon Abstract: Background/Objectives: RNA-binding motif protein 3 (RBM3) is a cold-shock protein associated with a favorable prognosis in various malignancies. However, its role in epithelial ovarian cancer (OC) remains unclear. This study aimed to evaluate the prognostic significance of RBM3 expression in OC and its association with clinicopathological features. Methods: We retrospectively analyzed 183 cases of OC. Tissue microarrays were constructed using paired 2 mm tumor cores, and RBM3 expression was assessed by immunohistochemistry. Nuclear staining was semi-quantitatively scored based on intensity and proportion, generating a nuclear score (NS). Cases were classified as high (NS > 1) or low (NS ≤ 1) expression. Associations with clinicopathological parameters and survival outcomes were analyzed using chi-square tests, Kaplan–Meier survival curves, and Cox regression models. Results: High RBM3 expression was observed in 51.4% of cases and was significantly associated with favorable histologic subtypes (mucinous, endometrioid, clear cell), early International Federation of Gynecology and Obstetrics (FIGO) stage, and the absence of distant metastasis. Subgroup survival analyses stratified by histologic subtype revealed no significant differences in survival outcomes. RBM3 expression was correlated with prolonged disease-free and overall survival, although it did not retain significance in multivariate analysis. Conclusions: RBM3 expression is strongly associated with favorable pathological features in epithelial ovarian cancer. Although not an independent prognostic marker, RBM3 may serve as a complementary biomarker for risk stratification and prognosis in clinical practice. 2024-12-31T15:00:00Z https://kumel.medlib.dsmc.or.kr/handle/2015.oak/46476 Title: A serum exosomal microRNA-based artificial intelligence diagnostic model for highly accurate detection of hepatocellular carcinoma Author(s): Jin-Seong Hwang; Sugi Lee; Gyeonghwa Kim; Hoibin Jeong; Kiyoon Kwon; Eunsun Jung; Yuna Roh; Taesang Son; Hana Lee; Moo-Seung Lee; Kyoung-Jin Oh; Hye Won Lee; Yu Rim Lee; Soo Young Park; Won Young Tak; Hyun Seung Ban; Hyun-Soo Cho; Mi-Young Son; Jang-Seong Kim; Keun Hur; Dae-Soo Kim; Tae-Su Han 2024-12-31T15:00:00Z https://kumel.medlib.dsmc.or.kr/handle/2015.oak/46401 Title: Diagnostic value of cytology in detecting human papillomavirus–independent cervical malignancies: a nation-wide study in Korea Author(s): Hye-Ra Jung; Junyoung Shin; Chong Woo Yoo; Eun Na Kim; Cheol Lee; Kyeongmin Kim; Ho-Chang Lee; Yonghee Lee; Ji Hye Kim; Soo Jin Jung; Yumin Chung; Joo Yeon Kim; Hye Eun Park; Tae Hoen Kim; Wonae Lee; Min-Sun Cho; Ran Hong; Yoon Jung Choi; Younghee Choi; Young Sub Lee; Sang-Ryung Lee; Myunghee Kang; Young Jin Seo; Seung-Sook Lee; Yoon-Jung Hwang; Hyun-Jung Kim Abstract: Background: Human papillomavirus (HPV) independent cervical malignancies (HPV-IDCMs) have recently been classified by the World Health Organization (WHO) 5th edition. These malignancies have historically received limited attention due to their rarity and the potential for evasion of HPV-based screening. Methods: We retrospectively reviewed 5,854 biopsy-confirmed cervical malignancies from 22 institutions over 3 years (July 2020–June 2023). Histologic classification followed the WHO guidelines. HPV independence was confirmed by dual negativity for p16 and HPV; discordant cases (p16-positive/HPV-negative) underwent additional HPV testing using paraffin-embedded tissue. Cytological results were matched sequentially to histological confirmation. Results: The prevalence of HPV-IDCM was 4.4% (257/5,854) overall and was 3.6% (208/5,805 cases) among primary cervical malignancy. Patient age of HPV-IDCM was 29 to 89 years (median, 57.79). Its histologic subtypes included primary adenocarcinoma (n = 116), endometrial adenocarcinoma (n = 35), squamous cell carcinoma (n = 72), metastatic carcinoma (n = 14), carcinoma, not otherwise specified (n = 10), neuroendocrine carcinoma (n = 3), and others (n = 7). Among 155 cytology-histological matched cases, the overall and primary Pap test detection rates were 85.2% (132/155) and 83.2% (104/125), respectively. The interval between cytology and histologic confirmation extended up to 38 months. Conclusions: HPV-IDCMs comprised 3.6% of primary cervical malignancies with a high detection rate via cytology (83.2%). These findings affirm the value of cytological screening, particularly in patients with limited screening history or at risk for HPV-independent lesions, and may guide future screening protocols. 2024-12-31T15:00:00Z